Argiris Athanasios

Argiris Athanasios Internist Oncologist

Director of 1st Internal Medicine - Oncology Clinic HYGEIA Hospital

Education & Academic Qualifications


  • Adjunct Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2014
  • Professor (tenured) and Chief, Division of Hematology-Oncology, A.B. Alexander Distinguished Chair in Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2011-2013
  • Visiting Professor of Medical Oncology, Department of Medicine, University of Crete, Herakleion, Greece, 2011
  • Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2009-2011
  • Associate Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2005-2009
  • Assistant Professor of Medicine Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2000-2005


  • ECFMG Certificate 0-458-528-7 for clinical practice in the U.S., 1994
  • Medical License for the states of Connecticut (1997), Illinois (2000), Pennsylvania (2005), Texas (2011)
  • Medical License for Attiki, Greece, 1991
  • Fellow of the American College of Physicians (FACP), 2005
  • ABIM board certified Medical Oncologist in the USA, 2000 and 2010 (recertified)
  • Official recognition of Medical Oncology specialty title in Greece, 2011
  • Doctor of Medicine Diploma, National & Kapodistrian University of Athens Medical School, Greece (1990)
  • Doctoral Thesis, National & Kapodistrian University of Athens Medical School, Greece, 2004


Fellowship in Societies, Membership in Journal Editorial Committees

  • European Organisation for Research and Treatment of Cancer (EORTC)

  • Eastern Cooperative Oncology Group (ECOG)

  • SWOG

  • National Cancer Institute (NCI Steering Committee)

  • Hellenic Society of Medical Oncology 

  • Hellenic Society of Head and Neck Oncology (HeSHNO)

  • Hellenic Society for Radiation Oncology 

  • American College of Physicians (ACP)

  • American Society of Clinical Oncology (ASCO)

  • American Association for Cancer Research (AACR)

  • International Association for the Study of Lung Cancer (IASLC)

  • European Society for Medical Oncology (ESMO)

  • EORTC, Head and Neck Cancer Group, member

AD-HOC REVIEWER for peer-reviewed international journals

  • Associate Editor, Head and Neck

  • Editorial Board, Journal of Clinical Oncology

  • Editorial Board, Anticancer Research

  • Editorial Board, Forum of Clinical Oncology

  • Editorial Board, Journal of Community and Supportive Oncology 

  • Editorial Board, Cancers of the Head and Neck


Work Experience

  • Chief, Division of Hematology/Oncology, Department of Medicine and Associate Director for Clinical Research, Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2011-2013

  • Co-Leader, Head and Neck Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 2005-2011

  • Disease Section Leader in Thoracic Cancer and Head and Neck Cancer, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, 2000-2005

  • Fellow in Medical Oncology/Hematology Yale University School of Medicine, New Haven, CT, 1997-2000

  • Resident in Internal Medicine Beth Israel Medical Center, New York, NY, 1994-1997

  • Resident in Radiation Oncology Areteion University Hospital, Department of Radiology, Athens, Greece, 1993-1994

  • Staff Physician in the Greek Arm Forces, 1991-1992

Education Experience:

  • Training of fellows in Medical Oncology

  • Training of Medical Oncologists and other specialists in thoracic and head and neck oncology


Clinical & Research Interest

Clinical relevance:

  • Lung Cancer 

  • Head and Neck Cancer 

  • Chemotherapy

  • Targeted Drugs

  • Combination Chemotherapy-Radiotherapy

Research interest:

  • Targeted and Personalized therapy

  • Novel agents

  • Phase I, II and III clinical trials

  • Principal Investigator in more than 50 clinical studies, ongoing or completed

  • Principal Investigator in ongoing studies with ECOG (E1305) and SWOG (S1206), USA

  • Funded by the National Cancer Institute, USA (R21 grant) to study head & neck cancer


Honors & Awards

  • ECOG Research and Education Young Investigator Award – 2009 (for leadership and substantial contributions to ECOG; requirement is less than 46 years of age) (2009)

  • Young Investigator Scholar Award for Clinical/Translational Research by the American Association for Cancer Research (2000)

  • SmithKline Beecham National Oncology Fellows’ Forum Travel Award (2000)

  • Faculty of 1000 in Medicine – 

  • Pittsburgh’s Magazine “Top Doctors” list 2008, 2009, 2010, 2011

  • America’s “Top Doctors” and “Top Doctors for Cancer” (Castle Connolly) 2008, 2009, 2010, 2011, 2012, 2013, 2014

  • Best Doctor U.S. News and World Report 2011, 2012, 2013, 2014



  • A. Argiris, J.R. Murren. “Clinical use of the camptothecins at year 2000”. Principles and Practice of Oncology Updates 2000; Volume 14; Number 2

  • A. Argiris. Small cell lung cancer module for the Physicians’ Information and Education Resource (PIER) of the American College of Physicians-American Society of Internal Medicine.

  • A. Argiris, J.R. Murren: “Staging and prognostic factors for small cell lung cancer”: In: Lung Cancer, Edition 2004

  • S. Laurie, A. Argiris: “Chemotherapy in the management of malignant tumors of salivary gland origin”: In: Salivary Gland Disorders, Editors: E. Myers, R. Ferris. Edition 2006 

  • M. Karamouzis, A. Argiris. “Targeting EGFR and VEGF in aerodigestive malignancies”. In: Cancer Metastasis: From Local Proliferation to Distant Sites Through the Lymphovascular System, Editor: Stanley P. L. Leong, Publisher: Humana Press/Springer, Edition 2007

  • M. Karamouzis, M. Gibson, A. Argiris. “The contribution of chemotherapy”. In: “Functional preservation and quality of life in head and neck radiotherapy”. Editor: P. Harari. Edition 2009

  • A. Kotsakis, M. Gibson, A. Argiris. “Incorporating novel agents with chemotherapy and radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck”. In: Current Multidisciplinary Oncology: Head and Neck Cancer. Editor, Robert I. Haddad. Edition 2010 

  • Guest Editor: “Lung Cancer” volume in “Emerging Cancer Therapeutic Series”. Demos Medical Publishing, LLC. Edition 2012

  • Guest Editor: “EGFR-targeted therapy for lung cancer”. Special Issue of Forum of Clinical Oncology 2012


Recent Publications

  • A. Argiris, M. Karamouzis, D. Raben, R. Ferris. “Head and neck cancer” Lancet 2008;371:1695-709.

  • S.S. Ramalingam, M. Maitland, P. Frankel, A.E. Argiris, M. Koczywas, B. Gitlitz, S. Thomas, I. Espinoza-Delgado, E.E. Vokes, D.R. Gandara, C.P. Belani. “Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)” Journal of Clinical Oncology 2010;28:56-62.

  • A. Tarhini, A. Kotsakis, R. Stoller, S. Dacic, W. Gooding, A. Argiris. “Phase II trial of everolimus in previously treated small cell lung cancer” Clinical Cancer Research 2010;16:5900-7.

  • A. Argiris, M.V. Karamouzis, W.E. Gooding, B.F. Branstetter, S. Zhong, L.E. Raez, P. Savvides, M. Romkes. “Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer” Journal of Clinical Oncology 2011;29:1140-45.

  • R.S Mehta, D. Lenzer, A. Argiris. “Race and health disparities in patient refusal of surgery for early stage non-small cell lung cancer: a SEER cohort study” Annals of Surgical Oncology 2012;19(3):722-7.

  • A. Argiris, A.P. Kotsakis, T. Hoang, F.P. Worden, P. Savvides, M.K. Gibson, W. Gooding, G.R. Blumenschein Jr., H.X. Chen, J.R. Grandis, P.M. Harari, M.S. Kies, S. Kim. “Cetuximab and bevacizumab: preclinical data and phase II trial in patients with recurrent or metastatic head and neck cancer” Annals of Oncology 2013 Jan;24(1):220-5.

  • A. Argiris, M. Ghebremichael, J. Gilbert, J. Lee, K. Sachidanandam, J. M. Kolesar, B. Burtness, A. A. Forastiere. “Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial” Journal of Clinical Oncology 2013 Apr 10;31(11):1405-14.

  • Ramalingam SS, Kotsakis A, Tarhini AA, Heron, D. E., Smith, R., Friedland, D., Petro, D.P., Raez, L. E., Brahmer, J. R., Greenberger, J. S., Dacic, S., Hershberger, P., Landreneau,R. J., Luketich, J. D., Belani, C. P., Argiris, A. “A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer”. Lung Cancer 2013; 81(3):416-421.

  • A. Argiris, S. Lu, M. Ghebremichael, A.M. Egloff, L. Wang, A.A. Forastiere, B.A. Burtness, R. Mehra. “Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative On-cology Group trials” Annals of Oncology 2014;24:1410-16

  • A. Argiris. “EGFR inhibition for recurrent and/or metastatic HNSCC” Lancet On-cology 2015;16:488-9